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Background: As part of its Family Planning 2020 commitment, the Nigerian government is aiming for a contraceptive prevalence
rate of 36% by 2018, and in 2014, approved a policy to allow community health extension workers (CHEWs), in addition to
doctors, nurses, and midwives, to provide contraceptive subdermal implants. There is a lack of rigorous evidence on the safety
of long-acting reversible contraceptive provision, such as implants, among lower cadres of health providers.
Objective: This study aimed to compare implant provision by CHEWs versus nurses and midwives up to 14 days post insertion.
Methods: The quasi-experimental, noninferiority study will take place in public sector facilities in Kaduna and Ondo States.
In each state, we will select 60 facilities, and from these, we will select a total of 30 nurses and midwives and 30 CHEWs to
participate. Selected providers will be trained to provide implant services. Once trained, providers will recruit a minimum of 8125
women aged between 18 and 49 years who request and are eligible for an implant, following comprehensive family planning
counseling. During implant insertion, providers will record data about the process and any adverse events, and 14 days post
insertion, providers will ask 4410 clients about adverse events arising from the implant. Supervisors will observe 792 implant
insertions to assess service provision quality and ask clients about their satisfaction with the procedure. We will conclude
noninferiority if the CI for the difference in the proportion of adverse events between CHEWs and nurses and midwives on the
day of insertion or 14 days post insertion lies to the right of −2%.
Results: In September and October 2015, we trained 60 CHEWs and a total of 60 nurses and midwives from 12 local government
areas (LGAs) in Kaduna and 23 LGAs in Ondo. Recruitment took place between November 2015 and December 2016. Data
analysis is being finalized, and results are expected in March 2018.
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Conclusions: The strength of this study is having a standard care (nurse and midwife provision) group with which CHEW
provision can be compared. The intervention builds on existing training and supervision procedures, which increases the
sustainability and scalability of CHEW implant provision. Important limitations include the lack of randomization due to nurses
and midwives in Nigeria working in separate types of health care facilities compared with CHEWs, and that providers self-assess
their own practices. It is unfeasible to observe all procedures independently, and observation may change practice. Although
providers will be trained to conduct implant removals, the study time will be too short to reach the sample size required to make
noninferiority comparisons for removals.
Trial Registration: ClinicalTrials.gov NCT03088722; https://clinicaltrials.gov/ct2/show/NCT03088722 (Archived by WebCite
at http://www.webcitation.org/6xIHImWvu)
(JMIR Res Protoc 2018;7(3):e67)   doi:10.2196/resprot.8721
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Introduction
In 2012, an estimated 222 million women had an unmet need
for modern contraception [1]. Meeting this need would avert
an estimated 218 million unintended pregnancies and 118,000
maternal deaths [1]. Nigeria has a large (191 million in 2017)
and rapidly increasing population [2] and a high maternal
mortality ratio, estimated to be 576 per 100,000 live births in
2013 [3]. In 2013, 15% of currently married women aged
between 15 and 49 years were using some method of
contraception, a figure considerably lower than the global (63%)
and sub-Saharan Africa (27%) estimates for the same year, and
16% had an unmet need for contraception [3].
There are many inequities in contraceptive access, with lower
levels of use among women in rural and remote areas, and
among those who are poorer, less educated, and younger [4].
In Nigeria, contraceptive prevalence is just 9% in rural areas
versus 27% in urban areas [3]. In addition, the most effective
contraceptive methods are often the most difficult to access [5].
Long-acting reversible contraceptives (LARCs), such as
intrauterine devices (IUD) and implants, are the most effective
reversible methods of contraception, with failure rates of
between 0.05% and 0.8% in the first year of use (contraceptive
pills have a failure rate of 8%) [6]. LARCs also have lower
discontinuation rates than short-term methods (such as the pill,
injectable, and condom) [5] and generally have high user
satisfaction [7]. In sub-Saharan Africa, unlike Asia and North
America, short-term contraceptive methods dominate [8]. In
Nigeria in 2013, 9.8% of currently married women were using
a modern method of contraception, and most (7.1%) were using
short-term methods; just 1.1% were using an IUD and 0.4% an
implant [3].Contraceptive implants consist of flexible
matchstick-sized rods, inserted below the skin on the
nondominant upper arm. They release small amounts of
progestin hormone to prevent pregnancy for 3 to 5 years [9].
Insertion is quick and does not require pelvic examinations or
laboratory tests. Complications are rare (although may include
infection at the insertion site, expulsion, or difficult removal),
and once inserted, implants require no regular action by the user
or health system [6].
Key barriers to LARC use include lack of availability (of method
or skilled providers), perceived cost, and misperceptions about
risks and benefits [5,10,11]. Low LARC availability has been
driven by lack of trained providers and, in the case of implants,
high commodity costs [12]. In recent years, costs have fallen
[13] but low provider numbers remain: the African continent
faced an estimated shortage of 4.2 million health care workers
in 2013 [14]. Shortages are more acute in rural areas: whereas
the national average number of doctors per 100,000 population
in Nigeria was estimated to be 12 in 2007, in the more rural
northwest and northeast, the ratio was only 4 [15]. Task-shifting
or task-sharing is a strategy recommended by the World Health
Organization (WHO) to address health worker shortages [16].
This involves expanding specific tasks, where appropriate, from
highly qualified health workers to those with shorter training
and fewer qualifications [17]. Task-sharing of implant services
has been implemented in several African countries [12]. After
a policy change allowed nurses, as well as physicians, to provide
implants in Tanzania, insertion rates increased from around
10,000 per quarter in 2007 to more than 20,000 in 2009 [18],
and in Ethiopia, 15,000 rural community health extension
workers (CHEWs) have been trained to insert implants
(removals are still handled by higher-level cadres) [12].
In 2012, Nigeria’s Honorable Minister of Health announced a
goal to increase contraceptive prevalence to 36% by 2018 [19].
The priority activities are to train more health care workers to
provide injectables, implants, and IUDs [19] and to change
national policy to permit CHEW provision of implants [20].
CHEWs are health care staff who undergo a 36-month course
in a training institution approved by the Community Health
Practitioners Registration Board of Nigeria [20]. CHEWs may
be located in larger urban health centers, with nurses and
midwives, or at smaller health centers, working alone or with
another CHEW. In a pre- and posttest pilot study conducted in
Sokoto and Bauchi States in Nigeria to assess the feasibility of
training CHEWs to provide implants [21], 166 CHEWs were
trained for 2 to 3 weeks, and they inserted 3588 implants in 151
health facilities over 6 months. Most CHEWs achieved
competency in implant insertions after insertions with 4 to 5
clients. Clinical observations revealed that CHEWs performed
implant insertion tasks correctly at least 90% of the time for 16
out of 19 checklist items. The amount of information that
CHEWs provided clients increased between baseline and end
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line, and over 99% of surveyed clients reported being satisfied
with CHEWs’ services.
Making implants more widely available could reduce the unmet
need and contribute toward achieving the ambitious 2020
contraceptive prevalence rate goals (the percentage of women
of reproductive age who are married or in union and are
currently using or whose sexual partner is currently using a
modern method of contraception) set by many countries in
Africa and elsewhere at the family planning (FP) summit in
2012 [22]. A systematic review of the effectiveness and safety
of task-sharing for the delivery of injectable contraceptives,
contraceptive implants, IUDs, tubal ligation, and vasectomy in
low- and middle-income countries found little or no difference
between cadres, but admitted that only limited conclusions could
be drawn from the small number of eligible studies [23]. The
conclusion of this review and the recent policy change in Nigeria
mean that there is opportunity and need to evaluate the safety,
quality, and acceptability of implant services provided by
CHEWs in Nigeria.
Methods
Study Design, Aim, and Objectives
The aim of this quasi-experimental, noninferiority study was to
compare insertion of contraceptive implants (Implanon Classic
and Jadelle; Table 1) by CHEWs with nurses and midwives in
Nigeria.
The primary objective was to compare the safety of implant
insertions by CHEWs with that of midwives and nurses on the
day of the procedure and up to 14 days post insertion. Secondary
objectives were to: (1) compare the quality of implant insertions
by CHEWs with that of midwives and nurses; (2) compare client
acceptability of implant insertions by CHEWs with that of
midwives and nurses; and (3) assess acceptability of CHEW
provision of implants to other health staff, clinic managers, and
other key individuals such as policy makers.
For the purpose of this study, safety refers to implant insertions
that minimize risk and harm to service users. We hypothesize
that implant provision by CHEWs will be as safe and of high
quality as provision by existing cadres of implant providers.
Safety will be assessed by comparing rates of any adverse events
(ie, those with a minor, moderate, or severe impact on a
woman’s health) at the time of the procedure, or up to 14 days
post insertion (Table 2). As the study is evaluating the provider
and not the method itself, method-related adverse events such
as hormone-related changes to menstruation pattern, headaches,
and nausea will not be recorded; neither will the study examine
the effectiveness of the method.
We define quality as the degree to which a provider or facility
meets certain objective and subjective levels of health care
delivery standards. The term covers all aspects of clinical service
provision such as correct insertion, infection prevention, and
disposal procedures, as well as pre- and post counseling and
taking a client-centered approach. We define acceptability as
the level of satisfaction experienced with the service received
(in the case of the client) and the level of satisfaction with this
aspect of the job (in the case of the provider).
Study Implementation
This study is a partnership between Marie Stopes International
(MSI); Marie Stopes International Organisation Nigeria
(MSION); the Federal Ministry of Health of Nigeria (FMOH);
Kaduna and Ondo State Ministries of Health, Nigeria; the
WHO’s Department of Reproductive Health and Research
Geneva; and the University of Ibadan, Nigeria. Clinical training
and research components will be conducted by MSI and MSION.
MSION established its first clinic in Abuja in 2009 and now
serves women in 25 states. Its mission is to provide reliable
information to women about their FP options and to improve
their access to FP methods. MSION is one of the only providers
of LARCs in Nigeria. Services are delivered through clinics,
mobile outreach teams, a social franchise network of private
providers, and partnerships with government providers.
Site and Provider Selection
The study will take place in public sector facilities in 2 Nigerian
states, 1 in the north (Kaduna) and 1 in the south (Ondo). The
north and south of Nigeria differ in religious beliefs,
contraceptive prevalence rate, and availability of health care
providers, making it necessary to generate evidence in each
context. We will purposively select local government areas
(LGAs) in Kaduna and Ondo States for study participation by
excluding LGAs with overlapping interventions and, given the
extensive supervision needs of the study, hard-to-reach LGAs.
Facilities will be eligible if they provide referral services on site
or are located within 20 km of a referral facility, in case of
adverse events resulting in the need to refer clients; if there is
a provider interested in participating in the study who expects
to be in the facility for the 12-month period of client recruitment;
and if the facility has been providing FP in the previous 3 years
and does not currently provide implants. Larger urban centers
staffed by nurses, midwives, and CHEWs and smaller rural
health centers staffed by a nurse or midwife only will be eligible
for inclusion.
A total of 60 facilities will be selected in each state from eligible
facilities, yielding a total of 120 facilities. Where there are more
than the required number of eligible facilities, simple random
sampling will be used to select facilities for inclusion. At least
30 nurse or midwife-led facilities will be selected in each state
to allow inclusion of 30 nurses and midwives in the study. The
remaining 30 facilities will include as many CHEW-led facilities
as possible. From each CHEW-led facility, 1 CHEW will be
trained, and 1 nurse or midwife or 1 CHEW will be trained from
each nurse or midwife-led facility. The providers trained will
be the individuals responsible for providing FP services at their
facility.
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Table 1. Details of implant brands to be included in the study.
FormatLabeled duration of useCompositionProduct
2 rods, separate disposable trocar5 years150 mg levonorgestrel, 2 rodsJadelle
1 rod preloaded in trocar3 years68 mg etonorgestrel, 1 rodImplanon Classic
Table 2. Implant insertion adverse events to be recorded.
Day recorded relative to procedureDescription of adverse reaction
0Anaphylactic reaction to the implant
0Implant insertion unsuccessful on first or second attempt
0Implant breaks
0Palpitations resulting from the local anesthetic
14Expulsion of implant
14Paresthesia due to neural damage (numbness, tingling, tickling, pricking, or burning sensation at implant site)






0 and 14Hematoma or bruising requiring medical intervention
0 and 14Bleeding around the injection area
0 and 14Other adverse reaction requiring medical treatment or resulting in long-term incapacity or fatality
Intervention Implementation
The intervention will have 4 phases, which are discussed below.
Clinical Supervisor Training
A total of 12 clinical supervisors (qualified nurses or midwives
with extensive experience of implant service provision) will be
trained over 3 days. Training will cover how to train study
providers to provide implants, clinical supervision of study
providers, and the research study and data collection procedures.
Provider Training in Implant Provision and the Research
Clinical supervisors will train providers on counseling and on
insertion and removal of Implanon Classic and Jadelle. Training
will comprise classroom and clinic components and include a
written test. Training will be based on the FMOH’s
competency-based training package for LARCs. This involves
working with providers at different levels to bring them up to
the same level, and so the number of days of training can vary
[24]. The implant clinical training materials, previously only
used to train nurses and midwives, will be reviewed and adapted
if necessary for CHEWs. Training will be free for providers.
All providers will be trained on the study protocol for managing
adverse events, which is based on MSI’s adverse event standard
operating procedures. The protocol details when to refer clients
to a higher-level provider, particularly important for CHEWs
who may be working in clinics without a higher-level provider,
and adverse event support and reporting mechanisms. Any major
adverse event must be reported immediately to the MSION
clinical services manager, who will inform the study manager
and the MSI medical development team in London within 24
hours. For this study, moderate adverse events will also be
reported to the clinical services manager who will inform the
study manager. Reportable adverse events are shown in Textbox
1. Other conditions are to be reported if the level of adversity
is judged to be persistent or difficult to manage. The clinical
services manager will be responsible for ensuring any adverse
event reported is managed effectively.
MSION research staff will train providers on the research study,
including participant recruitment and consent, data collection,
and data storage. Full training (implant provision and research)
is expected to take approximately 8 days.
Supervised Provision
After training, the trainee can provide implants to clients at their
clinic only in the presence of a MSION clinical supervisor.
The trainee will encourage FP clients to attend on scheduled
days when the supervisor is present. Clients will be counseled
on the available methods, and if they choose an implant, they
will be given the option of Jadelle or Implanon Classic.
Supervision visits will take place every 2 weeks but exact
timings will depend on the volume of implant clients. After 5
successful supervised insertions of each brand of implant, the
trainee is accredited to insert implants without clinical
supervision.
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Textbox 1. Moderate and major adverse outcomes to be reported to ensure participant safety.
Moderate level of adverse event
• Partial expulsion of implant, putting the woman at risk of pregnancy
• Pain at insertion site continues for more than 1 week and requires further outpatient observation and medical intervention
• Bleeding that does not stop and requires a transfer to receive medical care
• Infection that persists after 7 days of antibiotic treatment (may require implant removal)
Major level of adverse event
• Complete expulsion of the implant resulting in pregnancy
• Palpitations from the local anesthetic
• Bleeding that requires hospital care or results in long-term health impacts
• Infection that requires hospital care or results in long-term health impacts
• Paresthesia that requires hospital care or results in long-term health impacts
• Scarring that requires hospital care or results in long-term health impacts
• Anaphylactic response to the implant
MSION staff will conduct demand-generation activities in the
local area to increase awareness of the range of contraceptive
methods available, including implants, to ensure that trainees
have sufficient clients. Activities may include in-facility
awareness raising on special days such as antenatal care,
immunization, and child welfare days, and recruiting designated
locals to encourage potential clients in their communities to
attend the nearest study facility for FP.
On the basis of MSION’s previous experience of conducting
training and supervision of midwives, nurses, and doctors, it is
expected that most providers will have been accredited for
insertion by the end of their first supervision visit. Additional
visits will be undertaken in cases where accreditation of insertion
is not achieved within the prescheduled supervision visit.
Unsupervised Provision
After accreditation, participating providers will start to offer
unsupervised implant services in their clinics and to recruit
clients to the study. Participating providers will be invited to
attend a monthly study meeting at the state level where they
will receive study updates and tools and, if necessary, additional
training. Providers will receive lunch and travel costs.
Supervision visits will still occur but they will be less often
following provider accreditation.
Participant Recruitment and Eligibility
Women requesting an implant from a participating facility will
be eligible to participate if they are aged between 18 and 49
years and are eligible to have the implant. On presenting at a
participating clinic, each client will be provided with
comprehensive FP counseling and offered all available FP
methods (balanced counseling technique) [25]. Participating
providers will invite all clients who request an implant, and
meet the inclusion criteria, to participate in the study, using a
study information sheet and consent form. If the client chooses
an implant, she will be offered Jadelle or Implanon Classic, and
the same service provider will do the insertion. Clients who
want an implant but do not want to participate in the study will
be advised of the nearest available facility providing this service.
Clients will be recruited until the sample size is reached
(anticipated to be approximately 7 months). Participants who
are asked to return for a 2-week follow-up visit will be
reimbursed for their travel costs. Women who do not return
after 14 days will be contacted by telephone (if they gave
consent to be contacted and a phone number). In total, 3 attempts
will be made to contact women by telephone before they are
considered lost to follow-up. Those who are contacted by phone
will be asked to attend the facility for the 14-day follow-up visit
or, if unable, to answer questions over the telephone.
The number of clients who refuse to take part and who withdraw
will be documented, along with the reason for refusal or
withdrawal where given. If they agree, very basic
sociodemographic data and the reason for refusal will be
recorded.
All health care staff at participating facilities will be eligible
for participation in semistructured in-depth interviews to assess
acceptability of CHEW implant provision. A range of staff types
(doctors, nurses, midwives, and CHEWs) will be approached
by a senior research staff member and asked for their willingness
to participate. Policy makers involved in FP will be contacted
individually by researchers and asked to participate in an
interview. All participants will be asked for their informed
consent before the interview.
Sample Size
Day of Insertion
Calculation of the number of participants required for the study
is based on the primary outcome—the frequency of adverse
events associated with insertion on the day of the procedure.
Studies documenting adverse events of implant insertion on the
day of procedure have found them to be rare. For example, a
randomized clinical trial of 2008 women found that 0.2% clients
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using Jadelle and 0.8% clients using Implanon Classic
experienced complications at insertion [26].
To detect a difference in proportion of adverse events between
the 2 study arms with a noninferiority limit of 0.5%, 80% power,
and 95% confidence level on the day of implant insertion, we
would require a sample size of 2462 in each study arm, giving
a total sample size of 4924. To account for possible clustering,
we will include a design effect of 1.5, increasing the sample
size to 7386. To allow for incomplete records, we will increase
this by 10% to a total sample size of 8125.
We estimate that each provider will receive approximately 10
insertion clients per month and that we may see a refusal rate
of 20%. With a total of 120 providers, we expect to recruit 1200
clients per month. We would therefore need to recruit clients
for approximately 7 months to achieve the required sample size
for insertions.
By Day 14
We expect the number of adverse events observed by day 14 to
be higher than that at day 0 as we may start to see infections.
This reduces the required sample size needed to detect a
difference between health care provider types. To detect a
difference in proportion of adverse events between the 2 study
arms with a noninferiority limit of 1%, 80% power, and 95%
confidence level 14 days after implant insertion, we would
require a sample size of 1225 in each study arm, giving a total
sample size of 2450. To account for possible clustering, we will
include a design effect of 1.5, making the size 3675. Assuming
20% loss to follow-up makes a total sample size of 4410. If we
expect to recruit 1200 clients per month, it will take around 4
months to recruit the sample size we require.
All recruited clients will be asked to return to the inserting
provider for a follow-up visit at 14 days post insertion until the
sample size of 4410 is reached.
Quality and Acceptability of Implant Provision
To detect a difference in the quality and acceptability of implant
provision between the 2 study arms, assuming that each group
would score an average of 80% of quality and acceptability
indicators being met, with a noninferiority limit of 10%, 80%
power, and a significance level of 5%, we will need 198
observations in each group. Adjusting for 10% incompleteness,
we need 220 in each group (440 total). Assuming a design effect
of 1.8 requires a minimum of a total of 792 observed implant
insertions. There will be approximately 10 providers per
supervisor. So, assuming approximately 10% of insertions can
be observed (and client acceptability measured through exit
interviews), this equals 812 insertions, which is sufficient
according to the sample size calculation.
Acceptability of Community Health Extension Worker
Implant Provision to Health Staff, Facility Managers,
and Policy Makers
Approximately 3 to 5 interviews with providers from each cadre
will be conducted, until no new information or opinion is yielded
from each subsequent interview. Views from the north and
south, urban and more remote locations, and different ethnic
and wealth contexts will be included; if views are already
known, a mix of supporters and opponents of CHEW implant
provision will be interviewed.
Data Collection
Safety—Days 0 and 14
At the time of insertion, the provider will record baseline data
about the implant insertion, the occurrence of adverse events,
and the client’s background (including demographics,
socioeconomic information, reproductive history, and reasons
for getting an implant). At day 14 post insertion, the provider
will ask the client about side effects or complications arising
from the procedure.
To assess the ongoing safety of the study, any participant coming
to the facility with complaints about her implant up to 30 days
after the procedure will be asked a few questions by the provider
about what the participant has experienced and her responses
will be documented. Responses will be reviewed by project
staff.
Quality of Implant Provision
Each provider will be visited by her clinical supervisor at 0
(accreditation), 1, 2, 3, and 6 months post training. During these
1 to 2 day long visits, all implant insertions will be observed,
and data on quality recorded. Visits will be scheduled in advance
and previsit FP demand-generation activities will be conducted
by MSION and health care workers. The quality assessment
tool includes clinical and nonclinical dimensions, including
cleanliness, infection control, taking a client-focused approach,
and being responsive to client needs. The tool comprises a
checklist of 28 items, observed by the clinical supervisor. For
each item, the supervisor will assess provider competence (ie,
the provider knows the steps for the skills and can perform them
correctly or needs further follow-up) and support to achieve
competency (ie, the provider does not know the steps for the
skills and does not perform them correctly). The number of
items marked “competent” will be totaled to give the provider
a score.
Acceptability of Implant Provision—Client Exit
Interviews
During supervisor visits, clients participating in the study will
be interviewed by the supervisor in private, before leaving the
clinic. They will be asked to rate 7 aspects of service provision
on a 5-point scale, with responses being totaled to give a
satisfaction score. They will be asked if they would recommend
the service to a friend.
Data collection points are summarized in Table 3.
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Table 3. Summary of data collection procedures.
Sample sizeData to be collectedWho collects data, and howTiming of data collection
792Quality of service provisionSupervisor (if present), observes procedureAt the time of procedure
8125Client background, record of proce-
dure including complications at the
time
Community health extension worker (CHEW),
nurse or midwife who conducted procedure, ob-
serves client and asks her questions at clinic
Immediately post implant procedure
792Client satisfaction, completeness of
counseling information, critical infor-
mation provision
Supervisor (if present), conducts exit interview with
client
4410Complications following procedureCHEW, nurse or midwife who conducted proce-
dure, asks client questions at clinic or by telephone




Complications following procedureCHEW, nurse or midwife who conducted proce-
dure, records client’s problems at clinic
Within 30 days of procedure
Acceptability of Community Health Extension Worker
Implant Provision to Health Care Staff and Policy
Makers
Interviews with staff members and policy makers will cover
themes such as perception of confidence and competence in
CHEW provision of insertions, support for policy change,
perceptions of effectiveness of demand-generation activities,
supervision levels, supply chain, and cost-effectiveness.
Responses will be recorded on paper using shorthand notes with
verbatim quotes as far as possible, and audio-recorded as a
backup.
Data Management
Client identifiers, such as name or phone number, will be
recorded in a client register and will not be included on client
data collection forms. The 2 forms will be stored separately and
linked using a client identification number. Study documents
will remain in locked cabinets in the provider’s office, if
available, or in a secure location where medical records are
secured.
Providers will keep the anonymized data collection forms for
30 days after insertion and will record any spontaneous client
reports of adverse events over this 30-day period. After 30 days,
the anonymized forms will be sent to MSION head office in
Abuja. The client register will be kept at the clinic for the
duration of the study. At the end of the study, client registers
will be sent to MSION head office in Abuja and will be kept in
a locked cabinet separate from data collection forms. Completed
and anonymized exit surveys will be kept on the person of the
clinical supervisor or researcher conducting the interview until
the end of the visit, after which they will be sent to MSION in
Abuja.
Data entry will be conducted by an independent consultant
engaged by MSION. Paper forms will be checked for
completeness and obvious errors by the data entry clerk when
they arrive in Abuja, and queries will be checked by telephone
with the provider, clinical supervisor, or researcher. The data
entry clerk will double-enter all data into a password-protected
electronic database, verify any discrepancies between the 2 data
entries, and clean the data in preparation for safety monitoring
analysis every 3 months. When all complication data have been
collected, entered, and cleaned, the full dataset will be
transmitted to the research team in MSI London for analysis.
The cleaned, anonymized electronic dataset will be kept by MSI
London for a minimum of 5 years and will be made publicly
available by request to Marie Stopes [27]. Paper forms will be
kept securely by MSION in Abuja until 1 year after publication
and then destroyed.
Audio recordings will be transcribed verbatim. The recordings
will be stored in locked cabinets until they have been transferred
to a computer, after which they will be destroyed.
Data Analysis
Quantitative data will be analyzed using statistical software
Stata, version 13 (Stata Corp. College Station, Texas). Complete
case analysis will be conducted. For safety monitoring,
complication rates by provider will be generated by the study
manager in Abuja every 3 months, to identify any providers
with unusually high complication rates. These data will be
checked and response activities will be agreed at the 3 monthly
technical advisory committee meetings to be held in Abuja,
which will be attended by staff from MSION and MSI, and
ministry of health officials.
Training and supervision data will be presented using descriptive
statistics. Insertion adverse events of CHEWs will be compared
for noninferiority against the complication rates of nurses and
midwives. To assess the equivalence between the nurses and
midwives and the CHEWs, the risk difference between the 2
provider types together with their 95% CI will be derived by
use of a generalized estimating equation model to adjust for
clustering. If the CI of the risk difference between the 2 groups
falls within the predetermined margin of equivalence (–2% to
2%, which is equivalent of lower bound of one side 97.5% CI),
the 2 types of service providers can be considered equivalent.
Sensitivity analysis will be designed to control for group
assignment bias among the 2 states. They will be analyzed both
separately and together to identify any differences in
performance between CHEWs in the northern state compared
with the southern state.
All quality and acceptability indicators will be weighted equally,
except for those most critical (infection prevention, correct
clinical technique, and advice on where to go in case of
JMIR Res Protoc 2018 | vol. 7 | iss. 3 | e67 | p.7https://www.researchprotocols.org/2018/3/e67/
(page number not for citation purposes)
Reiss et alJMIR RESEARCH PROTOCOLS
XSL•FO
RenderX
problems), which will be given a higher weight. The difference
in mean quality and acceptability scores between CHEWs and
midwives will be compared using a t test.
Analysis of qualitative data will be undertaken manually or
using a qualitative analysis software such as N-Vivo. Quotations
will be labeled by cadre of speaker, and a thematic analysis will
be carried out. Transcripts will be read and reread. Extracts will
be coded according to themes and subthemes that emerge from
the data or that have been identified before the analysis such as
those included in the in-depth interview guide. A selection of
quotes representing different cadres and views will be used to
write a report structured around these themes.
Dissemination Policy
Findings will be shared with stakeholders through formal reports
and presentations at local and national levels, and more broadly
through peer-reviewed publications and international conference
presentations. Authorship eligibility will be dependent on
substantial contributions to planning, implementing, analyzing,
or drafting of findings. The deidentified dataset will be made
publicly available following the publication of study results.
Results
In total, 12 LGAs were selected in Kaduna State and 23 in Ondo
State. We trained 60 CHEWs and a total of 60 nurses and
midwives (30 of each from each state) in September and October
2015, and recruitment took place between November 2015 and
December 2016. Data cleaning is complete and analysis is being
finalized. Results are expected in March 2018.
Discussion
Besides resulting in 120 more health care staff qualified to
provide contraceptive implants, this study will provide robust
evidence on the safety, quality, and acceptability of
contraceptive implant provision by CHEWs compared with
nurses and midwives in Nigeria. This evidence may also serve
to support future decision making about task-sharing implant
services to community health workers in other countries.
Strengths of the study include being able to compare CHEW
provision with an existing standard of care (nurse and midwife
provision). The study builds on existing training and supervision
procedures, which will increase the sustainability and scalability
of CHEW implant provision if the results are promising.
The main limitations of the study are the lack of randomization
and that that providers will be assessing their own practices.
Clients cannot be randomized because they usually access their
local area clinic, and providers cannot be randomized because
they work at either CHEW-led or at nurse- or midwife-led public
clinics. Where both cadres work together, the national policy
is to train 1 provider in each clinic. This could result in bias due
to nonequivalence of the intervention and control groups (ie, if
participating CHEWs tend to work in more remote clinics with
poorer supply chain for infection prevention supplies than
participating nurse and midwives). It is not feasible to arrange
independent observation of all procedures; furthermore,
observation itself may change practice. Bias will be assessed
by comparing adverse event rates recorded by supervisors with
those documented by providers themselves. Providers will be
informed that this checking will take place.
Although both CHEWs and the nurses and midwives will be
trained in and will conduct implant removals, there will be
insufficient time during the study period to collect enough
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